Venus Remedies Share Price

Venus Remedies Limited (VRL) is a research-driven pharmaceutical company engaged in the pharmaceutical business in India and internationally. The company is one of the few players in the sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi (India), and a research and development centre under the name of Venus Medicine Research Centre. The Venus Remedies share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Venus Remedies stock price often mirrors shifts in domestic pharmaceutical demand, export trends, and investor views on the healthcare sector’s growth prospects. Factors such as the pace of new product launches, competitive intensity from domestic and international players, regulatory changes from the CDSCO, and government policies on drug pricing influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Venus Remedies stock price movements.

Venus Remedies live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Venus Remedies live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Venus Remedies share price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Venus Remedies Limited Company Fundamentals

a. Company Background

Venus Remedies Limited was incorporated in 1989. The company’s registered office is located in Chandigarh, India. The company was formerly known as Venus Glucose Pvt Ltd, was converted into a Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary & Family. Venus Remedies’ primary activity involves the research, development, manufacturing, and marketing of pharmaceutical formulations with a focus on specialized therapeutic areas including anti-infectives (antibiotics), oncology, neurology, pain management, and skin and wound care. The company initially focused on I/V Fluids & Injectables, with production starting in 1991 at Panchkula district in Haryana. In 1994 it introduced Eye/Ear/Nose drops. The company received the certificate as WHO-GMP as specified by WHO,Geneva. Venus Remedies set up a Cephalosporin project with an Australian collaboration with US-FDA standards at a cost of Rs.4.5 crores. In 2005-06, it commenced commercial operations at its most modern and techno-savvy manufacturing unit at Baddi, formed a wholly-owned subsidiary (WOS) in Germany, and acquired a running, German-GMP certified pharmaceutical unit at Werne, Germany. The company has a workforce of approximately 1,190 employees.

b. Product Lines

• Anti-infectives (antibiotics) for treatment of bacterial infections

• Oncology products for cancer treatment

• Neurology medications for neurological disorders

• Pain management products including analgesics and anti-inflammatory drugs

• Skin and wound care products for dermatological and wound healing applications

• Intravenous/Intramuscular injectable forms across various therapeutic categories

• Eye/Ear/Nose drops for ophthalmic, otic, and nasal applications

• Animal Health Division products including Megox-3000, Paroxin-3000, Pisa-3000, Mical, Ronid, Dexolyte, and Detox

c. Company Revenue Model

• Primary revenue from the sale of pharmaceutical formulations to domestic and international markets

• Volume-driven revenue based on quantity of drugs sold to hospitals, pharmacies, and distributors

• Pricing determined by regulatory frameworks (NPPA) and competition, affecting overall revenue generation

• Revenue from exports to international markets including Germany and other countries through wholly-owned subsidiaries

• Expanding geographical footprint contributing to new customer acquisition and revenue streams

• Focus on increasing product portfolio across multiple therapeutic segments to drive higher sales

• Investment in manufacturing facilities and quality certifications to enhance product offerings

• Revenue from contract manufacturing and research & development services

• Seasonal variations in demand for certain therapeutic categories affecting revenue patterns throughout the year

• Government policy changes on drug pricing and healthcare spending influencing revenue stability

d. Geographic Presence

• Strong presence across India with manufacturing facilities located in Panchkula (Haryana) and Baddi (Himachal Pradesh)

• Registered office and corporate headquarters located in Chandigarh

• Research and development centre under the name of Venus Medicine Research Centre in India

• International presence through wholly-owned subsidiary in Germany and acquisition of a German-GMP certified pharmaceutical unit at Werne, Germany

• Export presence in international markets through distribution networks and subsidiaries

• Digital platform enabling customer acquisition across domestic and international markets

• Operations primarily concentrated in India with growing international footprint through German subsidiary

e. Key Milestones

• 1989: Incorporated as Venus Glucose Pvt Ltd

• 1991: Production started with Intravenous/Intramuscular injectable forms at Panchkula, Haryana

• 1994: Converted into a Public Limited Company; introduced Eye/Ear/Nose drops

• 1994: Name changed to Venus Remedies Limited

• 2001: Introduced 13 new products in Animal Health Division with help of Product Development Committee (PDC)

• 2005-06: Commenced commercial operations at Baddi manufacturing unit; formed WOS in Germany; acquired German-GMP certified pharmaceutical unit at Werne, Germany; launched second R&D centre

f. Industry Perspective

Venus Remedies Limited operates in the pharmaceutical industry. Globally, the pharmaceutical market was valued at approximately USD 1.5 trillion in 2025 and is projected to grow at a CAGR of 3-6% through 2026. In India, the pharmaceutical market is a key driver of economic growth. According to Pharma Trac, the Indian pharmaceutical market (IPM) has registered a growth of 8.1 percent to touch ₹2,40,672 crore in 2025 and is likely to maintain the same growth range (7.8-8.1%) during the current year 2026. According to Mordor Intelligence, the India pharmaceutical market stands at USD 66.66 billion in 2025 and is forecast to reach USD 88.86 billion by 2030, advancing at a 5.92% CAGR. The sector’s annual turnover reached Rs. 4.72 lakh crore in FY25, with exports growing at a CAGR of 7 per cent over the last decade (FY15 to FY25). Anti-infectives hold a 19.6% market share in the India pharmaceutical market in 2024. The government aims to increase healthcare spending and access, with the AB-PMJAY scheme receiving increased allocation. Key challenges include regulatory compliance, pricing pressures from the National Pharmaceutical Pricing Authority (NPPA), intense competition from domestic and multinational players, and the upcoming Drugs, Medical Devices and Cosmetics Bill, 2023.

Venus Remedies Limited Stock Market Presence: Listings & Index Representation

Venus Remedies is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol VENUSREM and on the Bombay Stock Exchange (BSE) with the scrip code 526953. The company’s ISIN number is INE411B01019. Its listing on both exchanges ensures that the Venus Remedies price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company forms part of several benchmark indices that represent broad market segments. Venus Remedies is included in indices such as S&P BSE 500, S&P BSE AllCap, and S&P BSE SmallCap on the BSE. Being represented in multiple indices enhances the visibility and liquidity of the Venus Remedies stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s pharmaceutical landscape. The inclusion of Venus Remedies in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Venus Remedies Limited Stock Performance and Share Price History

The Venus Remedies price has exhibited significant volatility over the past decade, shaped by the company’s position in the pharmaceutical sector and broader industry cycles. The Venus Remedies share price recorded a 1-year total return of approximately 188.43% (price return) as of April 2026, significantly outperforming the Nifty 50 which provided a return of -2.65% during the same period. The Venus Remedies share price delivered a 5-year total return of 214.65% and a 10-year total return of 214.65% (based on available data), demonstrating substantial long-term wealth creation. The Venus Remedies share price reached a 52-week high of ₹1,025.75 on the NSE and ₹1,009.15 on the BSE, and a 52-week low of ₹285.70 on the BSE and ₹293.05 on the NSE, indicating a wide trading range and substantial price fluctuations of approximately ₹740 from peak to trough. The Venus Remedies share price recorded a strong rally in 2025 and 2026, delivering a 1-month return of approximately 37.63%, a 3-month return of 15.01%, a 1-year return of 188.43%, and a 3-year return of 451.92%.

The Venus Remedies stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 686.89% year-on-year growth in net profit to ₹9.60 crore in Q2 FY2025-26, the Venus Remedies stock price showed a positive reaction. The Venus Remedies share price has shown a pattern of positive momentum in years when the company’s earnings exceeded expectations, while periods of earnings moderation or concerns over regulatory headwinds have contributed to consolidation in the Venus Remedies stock price. Corporate developments, including strategic announcements such as the company’s focus on specialized therapeutic areas including anti-infectives, oncology, neurology, pain management, and skin and wound care, have also influenced short-term fluctuations in the Venus Remedies share price. The Venus Remedies share price has shown a 10-year aggregate net profit of ₹91.82 crore (FY2016-FY2025 based on available data), reflecting the company’s sustained profitability over the long term. The Venus Remedies share price reached its 52-week high of ₹1,025.75 before declining to its 52-week low of ₹285.70, reflecting the volatility inherent in the pharmaceutical space. The Venus Remedies share price has shown a year-to-date return of approximately 37.63% as of April 2026, indicating strong positive momentum in the current fiscal year. Comprehending these patterns in the Venus Remedies share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Venus Remedies stock price movements illustrate how industry fundamentals, regulatory cycles, and investor expectations converge in market pricing.

The Venus Remedies share price has shown distinct seasonal patterns over the past decade. In terms of annual performance, the Venus Remedies share price delivered its strongest returns in 2025 and 2026 following the post-pandemic pharmaceutical sector recovery. The Venus Remedies share price has demonstrated that the stock tends to perform better in periods of strong pharmaceutical demand and favourable export conditions, while underperforming during phases of regulatory uncertainty and intense competition.

Venus Remedies Limited Investor Relevance and Role in Portfolio

Venus Remedies holds a significant position for portfolio investors who seek exposure to India’s pharmaceutical sector with a focus on specialized therapeutic areas including anti-infectives, oncology, and injectables. The company’s strong R&D capabilities, international presence through its German subsidiary, and diversified product portfolio aligns it with investment strategies that value manufacturing scale and product innovation. The Venus Remedies share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor regulatory approvals, drug pricing trends, and healthcare spending indicators when evaluating allocation decisions.

Institutional stakeholders play a significant role in Venus Remedies’ ownership profile, with notable long term investment entities such as promoters holding 41.76% of the company. Foreign Institutional Investors (FIIs) hold 2.26% of the company, Domestic Institutional Investors (DIIs) hold 1.03%, and Retail holds 54.96% of Venus Remedies. Mutual fund holders of Venus Remedies include no mutual funds as mutual funds hold 0% stake in the company. FII holdings have increased from 1.34% in March 2025 to 2.26% in December 2025, while DII holdings have increased from 0% to 1.03% over the same period. Promoter holding has remained stable at 41.76% over recent quarters. These investors represent a blend of domestic and international perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.

The beta analysis of Venus Remedies across multiple time periods highlights its changing volatility in relation to the overall market. Based on data, the 1-month beta stands at 0.78, the 3-month beta at 0.84, the 6-month beta at 1.08, the 1-year beta at 1.37, and the 3-year beta at 1.66. Based on data from StockAnalysis, the beta is 0.31. Based on data from IndStocks, the Beta (LTM) is 0.97. Based on data from Simply Wall St, the stock’s weekly volatility (7%) has been stable over the past year. Based on data from TradingView, the stock has a beta coefficient of 0.04. The average weekly movement of Venus Remedies stock is approximately 7%, compared to the pharmaceutical industry average of 4-5% and the market average of 5-6%, indicating higher volatility than both its industry and the broader market. The Venus Remedies share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Venus Remedies stock price’s beta reflects that the company’s established market position and diversified product portfolio may provide some stability, though the pharmaceutical sector remains sensitive to regulatory changes and drug price fluctuations.

Venus Remedies Limited Sectoral Relevance and Peer Positioning

The sector relevance of Venus Remedies is anchored in its role within the broader Indian pharmaceutical industry, where it competes with other diversified drug manufacturing companies. As part of this industry, the company’s strategic positioning connects formulations across multiple therapeutic categories serving healthcare needs across domestic and international markets. Competitors in the pharmaceutical segment include companies such as Sun Pharmaceutical Industries Limited, Divi’s Laboratories Limited, Torrent Pharmaceuticals Limited, Cipla Limited, Aarey Drugs & Pharmaceuticals Ltd., and other specialized players. Firms with parallels in either product portfolio scale or manufacturing capabilities are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Venus Remedies P/E ratio have shown variations over different periods. The current P/E ratio of Venus Remedies stands at approximately 15.71 to 25.4 times, representing a 61% discount to its peers’ median range of 40.50 times. The Venus Remedies P/E ratio has shown significant fluctuations, with the ratio at 15.71 in April 2026, 25.4 in April 2026, 16.98 in some periods, and 21.70 in December 2023 as its highest in recent years.

Similarly, the Venus Remedies EPS narrative has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from capacity expansion and new product launches supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from raw material inflation and regulatory changes have moderated EPS momentum. Venus Remedies earnings have shown a trajectory that responded to both revenue growth and margin pressures over the analysed period. Venus Remedies market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving pharmaceutical market, currently standing at approximately ₹1,150 crore to ₹1,198 crore.

Over the last five years (FY2021 to FY2026), the market capitalisation of Venus Remedies has followed a pattern of significant growth. From fiscal year 2021 to 2025, the company’s market cap showed an increasing trend, reflecting strong investor confidence during the pharmaceutical sector boom. The market cap increased from approximately ₹1,150 crore in 2024-25 to ₹1,198 crore as of April 2026. The market cap has shown volatility, with values ranging from ₹1,150 crore to ₹1,198 crore in recent periods. This growth reflects investor confidence in the company’s strong product portfolio, manufacturing capabilities, and the overall growth of the pharmaceutical sector.

The earnings history of Venus Remedies over the past five years (FY2021 to FY2025) has been characterised by a period of consistent growth. Net income showed a generally increasing trend, with reported net profit rising from ₹21 crore in Dec 2024 to ₹24 crore in Dec 2025, representing a 14% year-on-year increase. For the full year FY2025, net profit stood at ₹45.31 crore. Total revenue increased from ₹587 crore in FY2024 to ₹647 crore in FY2025, a 11.17% year-on-year increase. Quarterly performance in Q3 FY2025-26 showed net profit of approximately ₹24 crore with revenue of ₹179 crore. Q2 FY2025-26 showed net profit of ₹20.13 crore with revenue of ₹192.75 crore, while Q1 FY2025-26 showed net profit of ₹9.60 crore with revenue of ₹131.90 crore. This consistent earnings performance reflects the impact of strong demand for anti-infectives and oncology products, operational efficiency, and cost optimization on the company’s profitability.

The Earnings Per Share (EPS) history for Venus Remedies has shown an improving trend over the past decade. The diluted EPS growth rate has shown variation, with EPS at ₹57.09 TTM as of April 2026, ₹33.9 according to other sources, and ₹18 in Dec 2025 quarter. Over a five-year period, the company demonstrated consistent improvement in EPS, with average earnings per share growth of approximately 10-15% per year. The highest EPS was recorded in the TTM period at ₹57.09, while recent quarters have shown EPS of ₹18 in Dec 2025, ₹14 in Sep 2025, ₹8 in Jun 2025, and ₹11 in Mar 2025.

The Price-to-Earnings (P/E) ratio history of Venus Remedies has shown fluctuations over the five-year period. At the end of recent fiscal years, the P/E ratio varied, with 2025 at 16.17, 2024 at around 20, 2023 at around 25, and recent data at 15.71 to 25.4. The mean historical P/E ratio over the last five years has been around 20-25 times. The current P/E ratio stands at a significant discount to the industry peer median of 40.50 times, reflecting that investor expectations are adjusting to near-term earnings headwinds. The Venus Remedies share price has been influenced by these valuation metrics. The Venus Remedies stock price continues to be evaluated in the context of its earnings potential and market position.

Summary

Venus Remedies is a leading pharmaceutical formulations company in India listed on both the NSE and BSE, where the Venus Remedies share price reflects domestic healthcare spending cycles, drug pricing regulations, and export demand within the pharmaceutical sector. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader healthcare access themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s pharmaceutical market.